LncRNA GClnc1 may contribute to the progression of ovarian cancer by regulating p53 signaling pathway

Eur J Histochem. 2020 Nov 10;64(4):3166. doi: 10.4081/ejh.2020.3166.

Abstract

Ovarian cancer (OC) is one of the most prevalent and deadly types of gynecological malignancy. Since current treatments are not effective against OC, it is imperative to develop novel potential therapeutic targets for managing OC. In this study, we aimed to uncover the underlying molecular mechanism of long non-coding RNA (lncRNA) GClnc1 related to p53 signaling pathway in OC. The expression of lncRNA H19 GClnc1 was markedly higher in OC samples than the related normal tissues. Next, we found that lncRNA GClnc1 inhibited p53. In addition, the lncRNA GClnc1 overexpression promoted the cell proliferation and migration in vitro. Subsequently, p53 silencing obligated the effect of lncRNA GCln1 knock down on cell proliferation and migration. To sum up, LncRNA GClnc1 contributes to the progression of OC by regulating p53 signaling pathway. Meanwhile, our findings also suggested that lncRNA GClnc1 may serve as a novel therapeutic target for OC patients.

MeSH terms

  • Cell Movement / physiology
  • Cell Proliferation / physiology
  • Disease Progression
  • Female
  • Humans
  • Ovarian Neoplasms / metabolism*
  • RNA, Long Noncoding / metabolism*
  • Signal Transduction / physiology*
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • H19 long non-coding RNA
  • RNA, Long Noncoding
  • TP53 protein, human
  • Tumor Suppressor Protein p53

Grants and funding

Funding: This research was funded by startup project of clinical medicine in Guangzhou (20171A010334) and by Science and Technology Planning Project of Panyu in Guangzhou (2017-Z04-20).